MR2938 relieves DSS-induced colitis in mice through inhibiting NF-κB signaling and improving epithelial barrier
{{output}}
Damage to the epithelial barrier is among key processes contributing to initiation and chronic inflammation in inflammatory bowel diseases (IBD). Only management therapy exists for IBD (e.g., anti-inflammatory and immunomodulatory agents, JAK/STAT inhibitors),... ...
